Dr. Maria R. Tria Tirona
Claim this profileEdwards Comprehensive Cancer Center
Expert in Lung Cancer
Expert in Parotid Gland Cancer
36 reported clinical trials
96 drugs studied
Area of expertise
1Lung Cancer
Global LeaderStage IV
Stage III
Stage II
2Parotid Gland Cancer
Global LeaderStage IV
Stage III
HER2 positive
Affiliated Hospitals
Clinical Trials Maria R. Tria Tirona is currently running
Eribulin + Chemotherapy
for Bladder Cancer
This phase III trial compares the usual chemotherapy treatment to eribulin plus gemcitabine in treating patients with urothelial cancer that has spread from where it first started (primary site) to other places in the body (metastatic). Chemotherapy drugs, such as eribulin, gemcitabine, docetaxel, paclitaxel, and sacituzumab govitecan work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial aims to see whether adding eribulin to standard of care chemotherapy may work better in treating patients with metastatic urothelial cancer.
Recruiting2 awards Phase 3
Selumetinib + Olaparib
for Ovarian and Endometrial Cancer
This phase II ComboMATCH treatment trial compares selumetinib plus olaparib to selumetinib alone in women with endometrial or ovarian (fallopian tube and primary peritoneal) cancer that has come back (recurrent) or that remains despite treatment (persistent) and harbors a mutation in the RAS pathway. Selumetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep tumor cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. The addition of olaparib to selumetinib could increase the percentage of tumors that shrink as well as lengthen the time that the tumors remain stable (without progression) as compared to selumetinib alone.
Recruiting1 award Phase 2
More about Maria R. Tria Tirona
Clinical Trial Related8 years of experience running clinical trials · Led 36 trials as a Principal Investigator · 13 Active Clinical TrialsTreatments Maria R. Tria Tirona has experience with
- Pembrolizumab
- Carboplatin
- Paclitaxel
- Biospecimen Collection
- Gemcitabine Hydrochloride
- Nivolumab
Breakdown of trials Maria R. Tria Tirona has run
Lung Cancer
Parotid Gland Cancer
Non-Small Cell Lung Cancer
Breast Cancer
Breast cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
What does Maria R. Tria Tirona specialize in?
Is Maria R. Tria Tirona currently recruiting for clinical trials?
Are there any treatments that Maria R. Tria Tirona has studied deeply?
What is the best way to schedule an appointment with Maria R. Tria Tirona?
What is the office address of Maria R. Tria Tirona?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.